Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04986943 · ClinicalTrials.gov registry record
ABTHERA ADVANCE™ Use Without Wittman Patch
A clinical trial of Necrotizing Pancreatitis, sponsored by Wake Forest University Health Sciences.
- Completed
- Registry status
- 3
- Enrollment target
- 1
- Study location
NCT04986943: Completed study of Necrotizing Pancreatitis, sponsored by Wake Forest University Health Sciences.
NCT04986943 is a study of Necrotizing Pancreatitis that has completed, run by Wake Forest University Health Sciences. The registered enrollment target is 3 participants. The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04986943, a study of Necrotizing Pancreatitis, has completed, sponsored by Wake Forest University Health Sciences.
- COMPLETED
- Registry status
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
The objective of this study is to evaluate the use of the ABTHERA ADVANCE for patients requiring open abdomen due to necrotizing pancreatitis. The institutions traditional approach is to use the ABTHERA Open Abdomen dressing with Wittmann patch. However, the ABTHERA ADVANCE has shown in vitro to have improved tension on the abdominal wall that may obviate the need for costly Wittmann patch placement.
Primary Outcome
Determine the variable cost savings associated with use of ABTHERA ADVANCE™ without the use of Wittmann patch.
Conditions Studied
Interventions
- DEVICE Using ABTHERA Advance without a Wittmann Patch
Study Locations (1)
North Carolina
- Atrium Health - Charlotte
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2020-10-12 |
| Est. Completion | 2023-03-14 |
What the finished NCT04986943 record still lists
NCT04986943 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 3 participants, a relatively small participant target.
The record links to 1 condition, with Necrotizing Pancreatitis appearing as the primary indexed condition, and to 1 intervention - of which Using ABTHERA Advance without a Wittmann Patch is the first listed.
NCT04986943 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT04986943 about?
NCT04986943 is a clinical study titled "ABTHERA ADVANCE™ Use Without Wittman Patch". The objective of this study is to evaluate the use of the ABTHERA ADVANCE for patients requiring open abdomen due to necrotizing pancreatitis. The institutions traditional approach is to use the ABTHERA Open Abdomen dressing with Wittmann patch. However, the ABTHERA ADVANCE has shown in vitro to hav...
What is the current status of trial NCT04986943?
This trial is currently completed. The enrollment target is 3 participants. The study started on 2020-10-12. Estimated completion is 2023-03-14.
What conditions does trial NCT04986943 study?
This clinical trial studies the following conditions: Necrotizing Pancreatitis.
What interventions are being tested in trial NCT04986943?
The interventions under investigation include: Using ABTHERA Advance without a Wittmann Patch (DEVICE).
Who is sponsoring clinical trial NCT04986943?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04986943 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI